Literature DB >> 23949688

Combined excision, cryotherapy, and intraoperative mitomycin C (EXCRIM) for localized intraepithelial and squamous cell carcinoma of the conjunctiva.

Ahmet M Sarici1, Sema Arvas, Halit Pazarli.   

Abstract

BACKGROUND: To report the results of patients undergoing combined excision, cryotherapy, and intraoperative mitomycin-C (EXCRIM) for primary ocular surface squamous neoplasia (OSSN)
METHODS: A retrospective review of a non-comparative interventional case series. Histopathologically confirmed primary localized (less than four clock hours) OSSN treated with EXCRIM using adjuvant 0.02 % mitomycin-C (MMC) were included in the study. The main outcome measures were recurrence and complications related to MMC.
RESULTS: The study enrolled 28 eyes of 28 patients with OSSN with a median age of 64.5 (range 43 to 84) years. The mean tumor size was 6.9 × 4.35 mm. There was corneal involvement in 23 of 28 (82 %). Seven patients (21 %) had delayed epithelial healing. Two of eight patients (25 %) with squamous cell carcinoma (SCC) had positive lateral margins. There were no recurrences over a mean follow-up of 49 months (range 24 to 96).
CONCLUSION: The excision of OSSN combined with cryotherapy and intraoperative MMC is effective with a low recurrence rate. Long-term follow-up yielded favorable results.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23949688     DOI: 10.1007/s00417-013-2437-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  18 in total

1.  Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications.

Authors:  H C Russell; V Chadha; D Lockington; E G Kemp
Journal:  Br J Ophthalmol       Date:  2010-06-08       Impact factor: 4.638

2.  The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation.

Authors:  Charalambos S Siganos; Vassilios P Kozobolis; Emmanuel V Christodoulakis
Journal:  Cornea       Date:  2002-01       Impact factor: 2.651

3.  The 1998 Pan American Lecture. Intraocular invasion of conjunctival squamous cell carcinoma in five patients.

Authors:  J A Shields; C L Shields; K Gunduz; R C Eagle
Journal:  Ophthalmic Plast Reconstr Surg       Date:  1999-05       Impact factor: 1.746

4.  Treatment of ocular surface squamous cell intraepithelial neoplasia with and without mitomycin C.

Authors:  Emily S Birkholz; Kenneth M Goins; John E Sutphin; Anna S Kitzmann; Michael D Wagoner
Journal:  Cornea       Date:  2011-01       Impact factor: 2.651

5.  Long-term follow-up of invasive ocular surface squamous cell carcinoma treated with excision, cryotherapy, and topical mitomycin C.

Authors:  Mohsen Bahmani Kashkouli; Abtin Heirati; Farzad Pakdel; Victoria Kiavash; Masood Naseripour; Farzaneh Aghamohammadi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-03       Impact factor: 3.117

6.  Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C.

Authors:  P J Dougherty; D R Hardten; R L Lindstrom
Journal:  Cornea       Date:  1996-09       Impact factor: 2.651

7.  Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia.

Authors:  G Tabin; S Levin; G Snibson; M Loughnan; H Taylor
Journal:  Ophthalmology       Date:  1997-03       Impact factor: 12.079

8.  Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.

Authors:  Amber Sturges; Amir L Butt; James E Lai; James Chodosh
Journal:  Ophthalmology       Date:  2008-02-21       Impact factor: 12.079

Review 9.  Conjunctival lesions in adults. A clinical and histopathologic review.

Authors:  H E Grossniklaus; W R Green; M Luckenbach; C C Chan
Journal:  Cornea       Date:  1987       Impact factor: 2.651

10.  Fungal scleral keratitis and endophthalmitis following pterygium excision.

Authors:  Vasileios Peponis; Pinchas Rosenberg; Spyridon E Chalkiadakis; Michael Insler; Apostolos Amariotakis
Journal:  Eur J Ophthalmol       Date:  2009 May-Jun       Impact factor: 2.597

View more
  9 in total

Review 1.  Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature.

Authors:  Charudutt Kalamkar; Nishant Radke; Amrita Mukherjee; Snehal Radke
Journal:  BMJ Case Rep       Date:  2016-05-10

2.  Topical Mitomycin-C Chemotherapy in Ocular Surface Squamous Neoplasia.

Authors:  Charudutt Kalamkar; Nishant Radke; Amrita Mukherjee; Snehal Radke
Journal:  J Clin Diagn Res       Date:  2016-09-01

3.  Update on the Management of Ocular Surface Squamous Neoplasia.

Authors:  Umangi Patel; Carol L Karp; Sander R Dubovy
Journal:  Curr Ophthalmol Rep       Date:  2021-02-20

4.  Bilateral ocular surface squamous neoplasia with bilateral periocular basal cell carcinoma in a case of xeroderma pigmentosum.

Authors:  Rohit Agarwal; Bhavna Chawla; Mohamed Ibrahime Asif; Amar Pujari
Journal:  BMJ Case Rep       Date:  2017-12-02

5.  Diagnosis and Medical Management of Ocular Surface Squamous Neoplasia.

Authors:  Ibrahim O Sayed-Ahmed; Sotiria Palioura; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2016-12-05

6.  Topical chemotherapy with mitomycin C in a feline corneal squamous cell carcinoma.

Authors:  Esmeralda Costa Delgado
Journal:  JFMS Open Rep       Date:  2020-05-27

Review 7.  Update on pharmacotherapy for ocular surface squamous neoplasia.

Authors:  Ghada Al Bayyat; Dan Arreaza-Kaufman; Nandini Venkateswaran; Anat Galor; Carol L Karp
Journal:  Eye Vis (Lond)       Date:  2019-08-12

Review 8.  Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence.

Authors:  Maria Vittoria Cicinelli; Alessandro Marchese; Francesco Bandello; Giulio Modorati
Journal:  Ophthalmol Ther       Date:  2018-07-20

9.  Molecular basis of Mitomycin C enhanced corneal sensory nerve repair after debridement wounding.

Authors:  Mary Ann Stepp; Sonali Pal-Ghosh; Gauri Tadvalkar; Luowei Li; Stephen R Brooks; Maria I Morasso
Journal:  Sci Rep       Date:  2018-11-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.